Pfizer | pharmaphorum

Friday 3 April 2026

Pfizer

News

AbbVie gets key FDA OK for migraine drug Qulipta

AbbVie gets key FDA OK for migraine drug Qulipta

AbbVie has carved out a niche for its migraine drug Qulipta in a competitive market, after claiming FDA approval for the product in the prevention of chronic migraine.

News

J&J decides not to play catch-up in RSV vaccination

J&J decides not to play catch-up in RSV vaccination

Johnson & Johnson has decided to bow out of the market for respiratory syncytial virus (RSV) vaccines, abandoning a late-stage development programme that would have be

News

GSK passes to Magic Johnson for RSV awareness drive

GSK said basketball legend will help spark “important conversations” about RSV in older adults.

News

GSK hits back in 5-in-1 meningitis jab contest with Pfizer

GSK hits back in 5-in-1 meningitis jab contest with Pfizer

Phase 3 trial sets up filing for GSK's MenABCWY vaccine, several months later than its rival.

News

Rumour of Pfizer, Seagen deal is true, with $43bn price tag

Rumour of Pfizer, Seagen deal is true, with $43bn price tag

Pfizer says Seagen's current and future drugs could add $10 billion to its revenues from 2030.

News

Pfizer’s migraine push builds with Zavzpret nod

Pfizer’s migraine push builds with Zavzpret nod

Zavzpret is first CGRP to be approved in a nasal formulation designed to be rapid acting.